Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 106, Issue 52, Pages 22504-22509Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.0912487106
Keywords
inflammation; insulin signaling; metabolic syndrome; nuclear hormone receptors
Categories
Funding
- Howard Hughes Medical Institute
- National Institutes of Health [HD027183, DK057978]
- Nuclear Receptor Signaling Atlas Grant [DK062434]
- Helmsley Charitable Trust
- British Heart Foundation
Ask authors/readers for more resources
Although peroxisome proliferator-activated receptorgamma (PPAR gamma) agonists such as thiazolidinediones (TZDs) are widely used to treat type 2 diabetes, how its activation in individual tissues contributes to TZD's therapeutic action remains controversial. As TZDs are known to have receptor-independent effects, we sought to establish gain-of-function animal models to delineate the receptor's insulin-sensitizing actions. Unexpectedly, we find that selective activation of PPAR gamma in adipocytes, but not in macrophages, is sufficient for whole-body insulin sensitization equivalent to systemic TZD treatment. In addition to improved adipokine, inflammatory, and lipid profiles, PPAR gamma activation in mature adipocytes normalizes serum insulin without increased adipogenesis. Co-culture studies indicated that PPAR gamma-activated adipocytes broadly suppress induction of inflammatory cytokines and C-X-C family chemokines in macrophages. Collectively, these data describe an adipocentric'' model in which adipose activation of PPAR gamma is sufficient for complete insulin sensitization and suggest a specific application for fat selective PPAR gamma modulators in diabetic therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available